Menu
Menu
Partner
Anthony is responsible for overseeing the fund’s investment decisions. He started his career as a boutique VC analyst. He later worked Monitor Deloitte, where he was responsible for M&A strategy for the world’s leading MNC’s. Anthony then moved on to strategy and business development leadership roles at Gilead Sciences and Jazz Pharmaceuticals.
Anthony holds an MBA from Columbia Business School
Partner
Kashif is a biopharma executive, with special expertise in evaluating commercial considerations for our portfolio companies. His expertise spans several decades of helping his clients maximizing the potential of their clinical assetsthrough external licensing and M&A. His prior experience includes leadership positions at IMS Consulting and Capgemini Consulting.
Kashif holds an MBA from Northwestern Kellogg
Partner
Mark is responsible for leading deal sourcing and due diligence in China and is responsible for managing the relationship with between our China investments and US NewCo’s. Mark was most recently VP of BD at GeneQuantum, one of China’s leading ADC development companies. He has also held leadership positions in business development at Kintor and Bayer.
Mark holds a B.A. from Fudan University.
Clinical Advisor
Stephen J. Peroutka, MD, PhD focuses on evaluating and providing strategic medical input for the US clinical development for our portfolio companies. Dr. Peroutka was most recently Vice President and Global Therapeutic Area Head at PPD, one of the world’s largest CRO’s. Prior to PPD, Dr. Peroutka held clinical leadership roles at Zogenix, Johnson and Johnson, and Genentech.
Dr. Peroutka holds M.D and Ph.D degrees from the Johns Hopkins University School of Medicine.
Anthony is responsible for HuntBest’s global strategy and partnerships. He has a wealth of experience overseeing cross-border biopharma deals. He started his career as a strategy consultant at Monitor Deloitte, where he was responsible for developing pipeline strategy for the world’s leading MNC’s. Prior to joining HuntBest, Anthony also held leadership positions in business development and strategy at Gilead Sciences and Jazz Pharmaceuticals. His experience working for and with many of the US’s leading biopharmaceutical companies provides valuable insight to HuntBest’s current and future portfolio companies.
Anthony holds an MBA from Columbia Business School, and a BS in chemistry from the University of California at Davis.
Ethan is responsible for HuntBest’s investments in novel technologies and modalities, with a particular lean towards SiRNA platforms. He has a long and successful track record as an executive in the healthcare CMC space, having served as the Vice President and Associate General Manager of Asymchem, a leading CDMO in China prior to joining HuntBest. While at Asymchem, he oversaw the clinical development and manufacturing of many of China’s leading pharmaceutical compounds. He currently also serves as a Council Member of the TongXieYi RNA Therapeutics Committee, where he is involved in the bleeding edge of new RNA therapeutics research.
Ethan holds a PhD in chemistry from the Chinese Academy of Sciences and has been published in journals such as JACS, ACIE, and ORPD during his time as an academic researchers.
Kevin founded HuntBest with the intention of providing both funding and expertise to undercapitalized and undiscovered entrepreneurs in China. His global vision for HuntBest has attracted a myriad of top-tier LP’s, corporate partnerships, and high-growth portfolio companies. Prior to founding HuntBest, Kevin held a leadership position at PrimaVera Capital, where he was responsible for deploying overseas investments and managing global partnerships. Prior to HuntBest, Kevin was an investment banker at Goldman Sachs, where he covered M&A transactions in the renewables space.
Kevin holds a PhD in chemistry from the Chinese Academy of Sciences, a post-doctoral from the University of Wisconsin, and an MBA from the Rotman School of Management.
Wenjun is responsible for managing the HuntBest’s domestic healthcare portfolio. He has a deep expertise in clinical operations and start-up investing, and serves as a board advisor to many of the companies he has invested in. Prior to HuntBest, Wenjun was an investment manager at Teda Venture Capital, where he oversaw venture investments into promising Chinese healthcare companies. Prior to Teda Venture Capital, Wenjun was a R&D project director as Asymchem, as leading Chinese CDMO, where he was responsible for ensuring timely and efficient clinical operations for his biopharmaceutical clients.
Wenjun holdTsinghuas a PhD in chemistry from Nankai University, and a post-doctoral at Georgia State University and University.
